Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Symphogen A/S

August 7, 2014
Sym004 Advances into Two New Clinical Trials and Receives Milestone Payments
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that its collaborative partner, Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, Merck Serono has initiated two new clinical studies evaluating Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). More

May 19, 2014
Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer
New Manufacturing Capabilities to Support early Development. More

June 26, 2013
Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration
Symphogen, ­­­­­­a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it has received a milestone payment from Merck KGaA, Darmstadt, Germany, related to the successful achievement of specific development objectives for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). More

June 2, 2013
Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody Mixture
ASCO Presentation and Poster on Sym004 in mCRC and SCCCHN. More

May 2, 2013
Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 million (USD 185 million)
Symphogen, ­­­­­­a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced €100 million financing. More

September 6, 2012
Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGa
A novel investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). More

September 4, 2012
Symphogen Enters Project Supported by the Danish National Advanced Technology Foundation
Symphogen Enters Project Supported by the Danish National Advanced Technology Foundation: Immune Antibody Repertoires in Microdroplets. More

June 10, 2011
Symphogen presents preliminary results from phase 2 clinical trial with Rozrolimupab
Symphogen presents preliminary results from phase 2 clinical trial with Rozrolimupab at the Annual European Hematology Association. More

March 7, 2011
Symphogen receives US patent on lead cancer compound Sym004
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics. More

January 6, 2011
Symphogen raises €100 million in private equity round
Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today that it closed a €100 million placement of Preferred Stock to a group of investors. More

December 7, 2010
Symphogen presents pre-clinical data on Sym004 program for EGF-receptor positive cancers
Symphogen will today present pre-clinical data on Sym004 program for EGF-receptor positive cancers at the IBC’s International Conference on Antibody Therapeutics in San Diego. More

September 16, 2010
Symphogen announces publication of data on the manufacture of polyclonal antibodies developed ...
Company issued European patent covering Sympress II manufacturing technology. More

July 13, 2010
Symphogen issued United States patent covering Symplex technology for antibody discovery
Symphogen A/S announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 7,749,697, titled 'Method for linking sequences of interest.' More

April 1, 2010
Symphogen announces initiation of Phase 1/2 trial of Sym004 in patients with advanced solid tumors
Symphogen announces initiation of Phase 1/2 trial of Sym004 in patients with advanced solid tumors in the US. More

November 3, 2009
Symphogen opens US operations in Princeton, New Jersey
US subsidiary supports expanding opportunities for Symphogen’s novel antibody pipeline and discovery and expression platforms. More

October 20, 2009
Symphogen appoints Jørgen Petersen as chief development officer
Antibody development veteran to oversee the clinical advancement of Symphogen’s novel antibody pipeline. More

August 17, 2009
Symphogen appoints Adriann Sax chief business officer
Seasoned executive will drive business development efforts for antibody discovery and expression platforms. More

December 4, 2008
Symphogen and Meiji Seika Kaisha Ltd. achieve milestone in discovery collaboration
Symphogen and Meiji Seika Kaisha Ltd. achieve milestone in discovery collaboration for recombinant polyclonal antibody, Sym006. More

December 1, 2008
Symphogen to present positive preclinical data on Sym004 program for EGF-receptor positive cancers
Results will be discussed at the European Antibody Congress in Geneva, December 2 and at the IBC's International Conference on Antibody Engineering in San Diego, December 11. More

July 16, 2008
Symphogen and Biovitrum have initiated a novel treatment study in ITP patients
Symphogen and Biovitrum have initiated a novel treatment study in autoimmune bleeding disorder (ITP) patients . More

February 6, 2008
Biovitrum and Symphogen have successfully completed phase I clinical trial
Biovitrum and Symphogen have successfully completed phase I clinical trial with recombinant polyclonal antibody More

December 4, 2007
Symphogen to present positive preclinical data on Sym003 program for RSV infection
Symphogen A/S today announced that John Haurum, Chief Scientific Officer, will present positive preclinical data on the Company's Sym003 program against respiratory syncytial virus (RSV) at IBC's 18th Annual International Conference on Antibody Engineering in San Diego. More

May 16, 2007
Symphogen appoints Ian Nicholson to Board of Directors
Symphogen A/S announced today that Ian Nicholson, B.Sc., MBA, has joined its Board of Directors. More

December 11, 2006
Symphogen and Meiji enter agreement
Symphogen and Meiji Kaisha enter agreement for recombinant polyclonal antibody product More

November 7, 2006
Symphogen Focus on Clininal Development
Symphogen appoints Christian Meyer vice president of clinical development
Dr. Henrik Rasmussen also appointed to Symphogen's Medical Advisory Board More

February 22, 2005
Symphogen strengthens patent position
New product patent covers polyclonal antibody compositions for allergy treatment More

Data


27,871
Tech investments
From our Online Data Service
17,963
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Mar 11
Kalysis
the world's most advanced bluetooth key for digital tachographs

Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.